The Opportunity
Precede Biosciences is seeking an exceptional scientific leader to serve as Vice President, Translational Cancer Epigenomics and External Research Partnerships. This role will define and lead the company’s translational strategy in oncology and other disease areas, translating discoveries in epigenomic biology into clinically impactful blood-based diagnostics.
The VP will serve as a key member of the scientific leadership team, responsible for advancing the biological and clinical understanding of Precede’s epigenomic platform and ensuring that insights generated across internal and collaborative research efforts translate into high-value diagnostic products and partnerships.
This individual will play a central role in shaping Precede’s scientific direction, building strong collaborations with academic investigators and biopharma partners, and guiding the development of next-generation assays that improve drug development and patient care.
About Us
Founded in 2021, Precede Biosciences is a diagnostic company pioneering a minimally invasive, comprehensive epigenomics platform. Our technology has the potential to profoundly impact the research and development of new medicines and getting the right therapy to the right patient at the right time. More information on our company and platform can be found on our company website and in our recent publication in Nature Medicine.
Our team cares deeply about creating a place where folks can do their best work from the start and have intentionally created an environment that is defined by purpose, teamwork, and excellence. This means nurturing team spirit, facing challenges together, collaboratively solving complex problems, while also ensuring a strong focus on individual initiative, accountability, and delivery.